Coronavirus (COVID-19) | Drugs

Español

The COVID-19 EUAs Listed on this Page Will No Longer be in Effect Beginning on 06/29/2027

On 06/29/2026, the HHS Secretary determined that circumstances no longer exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic. On the basis of this determination, the HHS declaration authorizing emergency use of drug and biological products for COVID-19 will be terminated, effective 06/29/2027. On the effective date of this termination (Emergency Use Authorization: Declaration, Drug and Biological Products during the COVID-19 Pandemic; Termination), the COVID-19 emergency use authorizations (EUA) for drug and biological products currently listed on this webpage will no longer be in effect.

The. U.S. Food and Drug Administration has approved several treatments for COVID-19, as described below.  In addition, more therapies are being tested in clinical trials to evaluate whether they are safe and effective for treatment or pre-exposure prophylaxis of COVID-19. 

COVID-19 Therapeutics

Types of FDA Approved Therapeutics for COVID-19

• Antiviral Drugs
  Antiviral drugs are medicines (pills, liquid, an inhaled powder, or an intravenous solution) that fight against viruses in your body.
• Immune Modulators
  Immune modulators are medicines that help activate, boost, or suppress the immune function. In the case of COVID-19 infection, the immune system can become hyperactive which may result in worsening of disease. Immune modulators can help suppress this hyperinflammation.

FDA Approved Drugs to Reduce the Risk of Hospitalization or Death for Patients with Mild to Moderate COVID-19

• Paxlovid (nirmatrelvir and ritonavir) is an antiviral drug, approved for certain adults and authorized under EUA for adolescents
• Veklury (remdesivir) in an antiviral drug, approved for certain adults and children

FDA Approved Drugs to Treat or Support Patients Hospitalized Due to COVID-19

• Actemra (tocilizumab) is an immune modulator drug, approved for certain adults and certain children
• Olumiant (baricitinib) is an immune modulator drug, approved for certain adults
• Veklury (remdesivir) is an antiviral drug, approved for certain adults and certain infants and children

Other Resources

• Know Your Treatment Options for COVID-19 
• Emergency Use Authorizations for Drugs
• CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19
• COVID-19 Therapeutics Expiration Dating Extensions
• Revoked and Terminated EUAs for COVID-19
• Coronavirus (COVID-19) | CBER-Regulated Biologics
• At-Home OTC COVID-19 Diagnostic Tests
• What Happens to EUAs when a public health emergency ends?

COVID-19 Treatment Hub

Provides physicians, patients, and caregivers with information about the latest research in the fight against COVID-19

COVID-19 Real World Data (RWD) Data Elements Harmonization Project

Mapping spreadsheet of COVID-19 data elements to several Common Data Models (CDMs) and open standards

FDA Sentinel System’s Coronavirus (COVID-19) Activities

Monitors the use of drugs, describes the course of illness among hospitalized patients, and evaluates therapies

CONTACT US

Division of Drug Information
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Building 51, Room 1109
Silver Spring, MD 20993

druginfo@fda.hhs.gov

Toll Free

(855) 543-3784

(301) 796-3400

Center for Drug Evaluation and Research (CDER)

For Latest Updates Follow

@FDA_Drug_Info

Your source for the latest drug information.
Know the moment it happens.